COVID-19大流行期间药物中断与后续疾病发作:风湿病患者纵向在线研究
本研究对2424例风湿病患者进行52周纵向在线随访,评估焦虑与改善病情抗风湿药(DMARD)中断趋势及DMARD中断与疾病发作的关联。结果显示PROMIS焦虑T评分从2020年4月的58.7降至2021年5月的53.7(趋势P<0.001),DMARD中断先降后升,中断与下次调查时严重发作(评分≥6/10)风险升高相关(OR 1.71,95%CI 1.23–2.36),但与任何发作无显著关联。
要点
- PROMIS焦虑T评分从2020年4月58.7降至2021年5月53.7(趋势P<0.001)。
- DMARD中断率从2020年4月11.2%降至12月7.5%,2021年5月升至14.0%。
- DMARD中断与下次调查严重发作相关(OR 1.71,95%CI 1.23–2.36),与任何发作无显著关联(OR 1.18,95%CI 0.89–1.58)。
核心结论
- 焦虑和DMARD中断最初随时间下降,但2021年DMARD中断增加,可能与COVID-19病例增加或疫苗可及性有关。
- DMARD中断与严重疾病发作率增加相关,强调避免不必要DMARD中断的重要性。
研究设计与样本
- ArthritisPower、血管炎患者驱动研究网络及其他患者组织邀请成员参加52周纵向研究。
- 基线调查于2020年3月29日至6月30日完成,随访至2021年5月。
- 采用广义估计方程的logistic回归评估DMARD中断与下次调查自我报告疾病发作的关联,并调整人口学特征、药物、疾病和日历时间。
主要发现
- 2424例患者完成中位5次随访调查,平均年龄57岁,87%为女性,最常见疾病为类风湿关节炎、血管炎和银屑病关节炎。
- 平均PROMIS焦虑T评分从2020年4月58.7降至2021年5月53.7(趋势P<0.001)。
- DMARD中断率从2020年4月11.2%降至2020年12月7.5%(P<0.001),但至2021年5月升至14.0%(P<0.001)。
- DMARD中断与下次调查严重发作(评分≥6/10)显著增加相关:中断组12.9% vs 未中断组8.0%(OR 1.71,95%CI 1.23–2.36)。
- DMARD中断与任何发作无显著关联(OR 1.18,95%CI 0.89–1.58)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to assess trends in anxiety and interruptions in disease-modifying antirheumatic drug (DMARD) use among patients with rheumatic diseases during the COVID-19 pandemic and to evaluate whether DMARD interruptions were associated with disease flares. METHODS: ArthritisPower, the Vasculitis Patient-Powered Research Network, and other patient organizations invited members to join a 52-week longitudinal study, with baseline surveys completed March 29 to June 30, 2020, with follow-up through May 2021. Logistic regression incorporating generalized estimating equations evaluated associations between interruptions in DMARD use and self-reported disease flares at the next survey, adjusting for demographic characteristics, medications, disease, and calendar time. RESULTS: Among 2,424 patients completing a median of 5 follow-up surveys, the mean age was 57 years, 87% were female, and the most common conditions were rheumatoid arthritis, vasculitis, and psoriatic arthritis. Average Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety T scores decreased from April 2020 (58.7) to May 2021 (53.7) (P < 0.001 for trend). Interruptions in DMARD use decreased from April (11.2%) to December 2020 (7.5%) (P < 0.001) but increased through May 2021 (14.0%) (P < 0.001). Interruptions in DMARD use were associated with a significant increase in severe flares (rated ≥6 of 10) at the next survey (12.9% versus 8.0% [odds ratio (OR) 1.71 (95% confidence interval [95% CI 1.23, 2.36]) although not any flare (OR 1.18 [95% CI 0.89, 1.58])]. CONCLUSION: Anxiety and interruptions in DMARD use initially decreased over time, but DMARD interruptions increased during 2021, possibly related to an increase in COVID-19 cases or vaccine availability. Interruptions in DMARD use were associated with increased rates of severe disease flares, highlighting the importance of avoiding unnecessary DMARD interruptions.
引用
- Dharia T, Venkatachalam S, Baker JF, et al. Medication Interruptions and Subsequent Disease Flares During the COVID-19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease. Arthritis Care Res (Hoboken). 2022. PMID: 34890121. doi:10.1002/acr.24837
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。